The plan was to lower drug costs for everyone. That was the plan. The reality? The biggest savings go to the uninsured who pay cash. A deal recently announced by President Trump promises to spare Americans over $600 billion across the coming decade, yet its specifics expose a twist requiring your attention. Uninsured cash payers buying direct-to-consumer are the main winners, per reports.
Trump announced this major step forward on Monday. Matching lowest costs from other developed nations for US drug prices is mandated by the new “most-favored nation” agreement. Nine more drugmakers accepted to sell products at these bottom costs, states the Washington Times. This brings the total number of manufacturers in the program to 26.
These deals cover 89% of the branded drug market. That is a huge chunk of the industry. The agreements bring relief for drugs that treat hemophilia, Parkinson’s disease, and various forms of cancer. It will also lower costs for drugs that control seizures and fight infections. The scope is massive, yet the mechanism is specific.
Why did this happen now? Trump argues the United States has been taken advantage of for too long. Noting US consumption of only 13% of global prescription drugs, he highlighted this fact. However, 75% of profits for drug companies originate from the United States. That is a massive imbalance.
“We were ripped off by the pharmaceutical companies, and we were ripped off more than anything by other countries throughout the world,” he said. Research from Rand Corp in 2024 indicates that prescription drug costs in the US are almost triple those found abroad. Overseas branded drug prices were less than one-fourth of the US amounts.
The new system flips the script. “But under that most favored nation agreement, we now pay the lowest price paid by other countries anywhere in the world,” Trump explained. The biggest price cut ever in our country’s history for prescription drugs is represented by these discounts. He claims the US has lost some very good friends by paying so much more than others.
Trump is not just making a deal; he wants to lock it in. He urged Congress on Monday to codify these pricing deals. He told lawmakers to act after announcing the new agreements. Mr. Trump stated his desire to make permanent his company-by-company pricing deals.
He cautioned that no future president could be imagined allowing deals to fall apart and drug prices to rise again. “It’s still a good idea to have it codified, to have it approved by Congress,” he said. The goal is to stop the cycle of high prices from returning once the current administration leaves.
State Medicaid programs will also receive select drugs at most-favored prices, as manufacturers agreed. This extends the reach beyond just cash-paying customers. The deals include major players like Pfizer, Eli Lilly, and Amgen, along with new names like Alcon and Teva Pharmaceuticals. The coverage is wide, but the savings are targeted.
The president says he deserves more credit for these historic decreases. He notes they mainly apply to uninsured Americans who pay cash and see large discounts on the TrumpRx website. This is the key detail that often gets missed in the headlines. The insured population might not see the same immediate drop in their co-pays.
For families paying out of pocket, this changes everything. A parent buying insulin or cancer medication at a pharmacy counter could see prices drop to match global lows. That is the promise of the deal. It is a direct hit on the companies that raised prices for decades.
The deal covers 26 drugmakers and 89% of the market. It is a historic shift in how America buys medicine. The savings are real, even if the path to them is specific. The uninsured get the biggest break, while the system moves toward global pricing norms. The question now is whether Congress will make it stick. The President has done his part. The rest is up to the lawmakers.
